Overview
Tempus is a precision medicine platform that ingests clinical records, genomics, imaging, and other data to generate AI-driven insights for oncology and broader disease areas. Its Tempus OS, diagnostics, and decision-support tools help clinicians choose targeted therapies, match patients to trials, and monitor disease using real-world and molecular evidence.
Pricing
Clinical Testing (Oncology Diagnostics)
- Tempus genomic and liquid biopsy tests (e.g., tissue NGS panels, ctDNA/xM assays) are typically billed in the 1,500–3,000 USD per test range before insurance.
- Actual out-of-pocket patient cost depends on insurance coverage, financial assistance, and institutional arrangements.
Biopharma & Trial Solutions
- Biopharma partners pay per-test fees (often 1,500–3,000 USD per patient for specialized assays) plus trial enrollment and activation fees (commonly 50,000–200,000 USD per trial).
- Additional revenue comes from data licensing on de-identified clinical and molecular datasets, estimated in the hundreds of millions annually.
Platform & Data Partnerships
- Health systems and researchers can license access to Tempus’ 25+ million clinical records and platform tools via bespoke contracts.
- Pricing is enterprise and project-based, reflecting scale, data access level, and integration depth.
Key Features
- Tempus OS – A modular precision medicine platform that lets providers and partners query multimodal data, run algorithms, and integrate with clinical workflows.
- Genomic & ctDNA testing – Comprehensive tumor profiling and ctDNA/xM assays used for diagnosis, therapy selection, and minimal residual disease monitoring.
- AI-enabled decision support – Algorithms that recommend potential therapies, highlight trial options, and flag care gaps at the point of care.
- Clinical trial matching & JIT activation – Systems that screen millions of patients to match them to trials and enable just‑in‑time site activation, dramatically cutting activation time.
- Data platform & research tools – Secure access to de-identified multimodal datasets for academic and biopharma research.
Best Use Cases
- Precision oncology – Selecting targeted therapies and immunotherapies based on tumor genomics and ctDNA signals.
- Clinical trial acceleration – Identifying eligible patients and shortening trial activation timelines across large health systems.
- Health system decision support – Embedding AI tools in EMRs to surface care gaps and guideline deviations in real time.
- Real-world evidence & biomarker research – Using large de-identified datasets to discover biomarkers and refine treatment pathways.
- Cardiology, psychiatry, and beyond – Applying similar precision approaches to other specialties like cardiology and depression.
Pros
- ✅ Massive multimodal data asset – Among the largest clinical + molecular data libraries, enabling powerful AI models.
- ✅ Deep oncology focus & results – Strong traction in cancer diagnostics, trial matching, and ASCO-level outcomes.
- ✅ Integrated platform approach – Combines testing, AI decision support, EMR integration, and research data in one ecosystem.
- ✅ Strong partnerships & funding – Collaborations with major pharma, health systems, and institutions like AstraZeneca and Illumina.investor.
Cons
- ❌ Enterprise and lab-centric pricing – High test and platform costs make Tempus primarily suitable for large systems and funded programs.
- ❌ Complex integration requirements – EMR integration, data sharing, and workflow changes require significant IT and change management.
- ❌ Regulatory and data governance demands – Operating at the intersection of genomics, AI, and clinical care brings heavy compliance overhead.
Official Website
Tempus – Official website and precision medicine platform: https://www.tempus.com
Release Date: Founded in 2015 by Eric Lefkofsky in Chicago; went public on Nasdaq (ticker “TEM”) in June 2024.
Last Updated: December 2025